Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
Yves DauvilliersEmmanuel MignotRafael Del Río VillegasYeting DuElizabeth HansonYuichi InoueHarisha KadaliElena KoundourakisSeetha MeyerRaquel RogersThomas E ScammellSarah I SheikhTodd SwickZoltan SzakácsPhilipp von RosenstielJingtao WuHeidi ZeitzN Venkatesha MurthyGiuseppe PlazziChristian von HehnPublished in: The New England journal of medicine (2023)
In a phase 2 trial involving patients with narcolepsy type 1, an orexin receptor 2 agonist resulted in greater improvements on measures of sleepiness and cataplexy than placebo over a period of 8 weeks but was associated with hepatotoxic effects. (Funded by Takeda Development Center Americas; TAK-994-1501 and TAK-994-1504 ClinicalTrials.gov numbers, NCT04096560 and NCT04820842.).